Evidence map›Paper›PMID 42571199›Full record

ArticleMultiple sclerosis journal - experimental, translational and clinical

Retinal atrophy in multiple sclerosis is similar with extended versus standard interval natalizumab therapy.

Brenna McCormack, Omar Ezzedin, Ting-Yi Lin, Anna Bacchetti, Giulia S Moretti, Ernest Lievers, Ananya Gulati, Simidele Davis, Gabriel Otero-Duran, Devon J Bonair and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Brenna McCormackDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0009-0002-6678-7021
Omar EzzedinDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Ting-Yi LinDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0001-9605-8095
Anna BacchettiDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0009-0000-9434-8531
Giulia S MorettiDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0009-0001-1532-5284
Ernest LieversDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Ananya GulatiDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Simidele DavisDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Gabriel Otero-DuranDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Devon J BonairDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Nicole PellegriniDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Georgios GakisDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-7339-4659
Angeliki FilippatouDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0003-0419-233X
Clare McGarvey LambertDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-1194-0538
Martin Maurice O'DonnellDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0001-7846-6597
Kathryn FitzgeraldDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0003-3137-0322
Elias S SotirchosDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-8812-1637
Peter A CalabresiDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-7776-6472
Scott D NewsomeDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-5284-4681
Ellen M MowryDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0003-0623-5188
Shiv SaidhaDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0001-6387-0714

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Retinal ganglion cell + inner plexiform layer (GCIPL) atrophy reflects global neurodegeneration and disability in multiple sclerosis. Extended interval dosing (EID; every 5-8 weeks) natalizumab reduces progressive multifocal leukoencephalopathy risk in people with relapsing-remitting multiple sclerosis (PwRRMS) versus standard interval dosing (SID; every 4 weeks). Objectives: To assess if EID versus SID natalizumab differentially impacts GCIPL atrophy, other retinal layer (peripapillary retinal nerve fiber layer (pRNFL), inner nuclear layer (INL), and outer nuclear layer (ONL)) atrophy, and/or clinical outcomes in PwRRMS. Methods: PwRRMS underwent longitudinal Cirrus high-definition optical coherence tomography (OCT), expanded disability status scale (EDSS), 100% and 2.5% contrast letter-acuity (LA) assessments. Analyses utilized mixed-effects regression models adjusting for age, sex, race, disease duration, optic neuritis history, and interval between treatment initiation and OCT monitoring, accounting for within-subject, inter-eye correlations. Results: GCIPL and pRNFL atrophy rates were not significantly different between EID ( Conclusion: We detected no significant difference in GCIPL or pRNFL atrophy, or clinical outcomes, between EID and SID natalizumab. Faster INL and ONL atrophy may relate to cohort demographic differences.

Indexed as

demyelinating diseasesMultiple sclerosisnatalizumaboptical coherence tomographyrelapsing–remitting multiple sclerosistysabri

Identifiers

PMID42571199
PMCPMC13451722

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.